India's Bulk Drug Makers Ramp Up CDMO Investments
Indian API manufacturers are shifting to high-value contract development, targeting $22-25 billion market by 2035 as global pharma diversifies from China. Read about the growth trajectory.
Category : Search result: CDMO
Pharma Chemical Firms Outperform with 7% Growth
Speciality chemical makers supplying pharma CDMOs post 7% sales growth, outpacing non-pharma peers. Strong margins and global shifts fuel this resilient sector. Read more.
Navin Fluorine Stock Up 80% on CDMO Growth, Export Boom
Navin Fluorine International rallies 80% in 2025 as CDMO revenues double, Darolutamide orders ramp up, and new capacity boosts FY26 outlook. Strong margin expansion fuels investor optimism.
Advent, Warburg bid for Encube in $2.3B stake sale
Global PE giants Advent and Warburg Pincus join Blackstone, KKR, EQT in race for Encube Ethicals stake. Promoters may sell alongside Quadria Capital in potential $2.3B valuation deal.
OneSource Pharma Raises FY28 Revenue Target to $500M
OneSource Pharma hikes FY28 revenue guidance to over $500 million, plans $100M expansion for weight-loss drugs like semaglutide. CEO reveals accelerated growth strategy.
Piramal Pharma Bets on US Biopharma Funding Revival
Piramal Pharma anticipates significant growth as US biopharma funding shows recovery signs, with CDMO business poised for major expansion.
Page 1 of 1